Dr Reddy’s, Cheminor merger: The right prescription - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • May 22, 2000 - Dr Reddy’s, Cheminor merger: The right prescription

Dr Reddy’s, Cheminor merger: The right prescription

May 22, 2000

It’s finally been announced: Cheminor Drugs (Cheminor) part of the Dr. Reddy’s group is to be amalgamated with Dr. Reddy’s Laboratories (DRL). This comes on the heels of the another merger: that of American Remedies (ARL) with DRL. Cheminor has been the main supplier of bulk drugs to the USA via its US subsidiary Reddy Cheminor Inc. (almost 67% of the turnover of the company, comprised exports to the USA). The company has capacities for Dextromethorpan (a cough suppressant), painkillers such as ibuprofen and naproxen (both used for arthritis), anti–ulcer medicines ranitidine and famotidine and diltiazem (a cardiovascular drug used for controlling blood pressure).

Cheminor has filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline. The company has set a target to file three to five ANDAs every year and have already received approval for ranitidine (75 mg), the anti–ulcerant omeprazole and anti–depressant fluoxetine.

The company has also been proactive on another plane viz. in filing suits challenging the existing product patent of the patent holders. Reddy Cheminor has filed patent suits against multinational giants Astra Zeneca (producer of omeprazole), Bayer (ciprofloxacin) and Eli Lilly (fluoxetine).

Cheminor reported a turnover of Rs 2154 m last year and the merger would lead a turnover of Rs 7084 m for the combined entity. This would also ensure better valuations for the DRL, which has announced plans for a $ 150–200 m ADR issue in the current financial year.


Equitymaster requests your view! Post a comment on "Dr Reddy’s, Cheminor merger: The right prescription". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 23, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS